Dose EScalation Induction of EvERolimus
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Hormone Receptor Positive Tumor
Interventions: DRUG: 3 weeks Dose Induction of Everolimus|DRUG: 3 weeks Conventional Everolimus Dosing|DRUG: Open Label Phase with conventional 10mg Everolimus Dosing week 4-24|DRUG: Standard Care after 24 weeks
Sponsor: German Breast Group
Collaborators: Novartis